Franklin Resources Inc. Has $343.35 Million Stake in Guardant Health, Inc. $GH

Posted by Francis Steltz on Jun 9th, 2026

Franklin Resources Inc. boosted its stake in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 14.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,361,547 shares of the company’s stock after buying an additional 435,232 shares during the quarter. Franklin Resources Inc.’s holdings in Guardant Health were worth $343,348,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in GH. V Square Quantitative Management LLC acquired a new stake in shares of Guardant Health in the fourth quarter valued at about $27,000. Chesapeake Asset Management LLC bought a new stake in Guardant Health in the fourth quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Guardant Health in the fourth quarter valued at approximately $31,000. Elyxium Wealth LLC acquired a new stake in Guardant Health during the 4th quarter valued at approximately $35,000. Finally, Parallel Advisors LLC raised its holdings in Guardant Health by 164.7% during the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

GH has been the topic of a number of recent analyst reports. Robert W. Baird started coverage on shares of Guardant Health in a research report on Tuesday, February 17th. They issued an “outperform” rating and a $120.00 price target on the stock. Stifel Nicolaus boosted their target price on shares of Guardant Health from $120.00 to $130.00 and gave the company a “buy” rating in a report on Friday, February 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research report on Tuesday, April 21st. Wolfe Research assumed coverage on Guardant Health in a report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price target for the company. Finally, JPMorgan Chase & Co. lifted their price objective on Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $139.80.

View Our Latest Research Report on GH

Insider Buying and Selling at Guardant Health

In other news, Director Steve E. Krognes sold 9,294 shares of Guardant Health stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $132.51, for a total transaction of $1,231,547.94. Following the completion of the transaction, the director directly owned 10,222 shares in the company, valued at $1,354,517.22. This trade represents a 47.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Meghan V. Joyce sold 10,000 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $126.98, for a total transaction of $1,269,800.00. Following the completion of the sale, the director owned 11,183 shares in the company, valued at $1,420,017.34. This represents a 47.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 452,238 shares of company stock worth $51,425,612 in the last ninety days. 5.60% of the stock is currently owned by corporate insiders.

Guardant Health Stock Down 0.6%

NASDAQ GH opened at $124.89 on Tuesday. Guardant Health, Inc. has a 52 week low of $40.35 and a 52 week high of $134.28. The business has a 50 day moving average price of $100.13 and a 200-day moving average price of $101.32. The company has a market cap of $16.56 billion, a price-to-earnings ratio of -36.84 and a beta of 1.61.

Guardant Health Profile

(Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.